The global oncology business unit of Takeda Pharmaceutical possesses a passion for improving patients’ lives, rooted in a strong heritage of science and innovation. We are changing expectations in science by focusing on treatments that address forms of cancer that haven’t traditionally been the focus of oncology R&D. This emphasis on cutting-edge science informs all aspects of our strategy, from early-stage research and clinical programs to our business development and collaboration approach.
Takeda’s proven commercialization capabilities allow us to quickly respond to the diverse and dynamic needs of patients, healthcare providers and health systems globally. We are a force of more than 2,000 dedicated oncology professionals, driven by a patient-focused entrepreneurial spirit and commitment to agility, even as our organization grows. We continually look for opportunities to collaborate with innovative and forward-thinking companies to quickly bring transformative therapies to market.
Finally, we’re changing expectations about what it means to partner with patients. We’ve redefined patient advocacy relations and our team cares about patients in a way that influences every decision we make. Understanding their journeys challenges us to continually bring better medicines to market.
Every day, we come to work committed to changing expectations through our relentless pursuit of game-changing science, forging the right partnerships and learning from successes and failures. We will continue to redefine paradigms and create a profound impact on patients’ lives. Our vision will not be achieved quickly or simply, but we are up to the task: We Aspire to Cure Cancer.